Pharmacovigilance (PV) is a critical function for ensuring patient safety and regulatory compliance in the pharmaceutical industry. For companies operating in the UK and EU, Good Pharmacovigilance Practice (GVP) audits are essential to evaluate whether your systems, processes, and staff are aligned with regulatory expectations from the MHRA, EMA, and other authorities.
Many organisations ask: “Do we really need a pharmacovigilance audit?” The answer is yes especially if there are gaps in compliance, new products, or recent regulatory changes. A PV audit helps identify risks, strengthens your systems, and ensures that safety reporting and risk management are fully compliant.
This article outlines key indicators that your organisation may need a pharmacovigilance audit and how it can help maintain regulatory confidence.
Read More: Internal vs External Audits in GMP and Pharmacovigilance: What UK Regulators Expect
1. Regulatory Changes or Updates
Regulations and guidance for pharmacovigilance are constantly evolving. For example, the MHRA regularly updates requirements for safety reporting, signal detection, and risk management.
Why this matters:
- Your PV system must remain aligned with current legislation and guidance.
- Failing to implement new regulatory requirements can lead to findings in inspections.
Solution: A GVP audit identifies gaps in compliance with recent regulatory updates, ensuring your processes and documentation are fully aligned.
2. New Products or Expanded Markets
Introducing new products, indications, or marketing authorisations increases the complexity of pharmacovigilance activities.
Key indicators for a PV audit:
- Recent product launches or line extensions
- Expansion into new territories or EU/UK markets
- Changes in reporting requirements or local regulatory obligations
Benefit: Auditing your PV system during product expansion helps prevent missed adverse event reporting and ensures all safety obligations are being met.
3. High Volume of Adverse Event Reports
A sudden increase in Individual Case Safety Reports (ICSRs), literature cases, or safety signals may indicate potential gaps in your PV process.
Why this triggers a PV audit:
- To confirm that triage, assessment, and reporting processes are robust
- To ensure timely submission of ICSRs to regulatory authorities
- To identify bottlenecks or inefficiencies in safety monitoring
Auditing these processes ensures that your PV system can handle workload increases without compromising compliance.
4. Previous Inspection or Audit Findings
Past MHRA, EMA, or internal audit observations often highlight areas where your PV system requires improvement.
Signs you need an audit:
- Open or recurring CAPAs related to pharmacovigilance
- Incomplete or inconsistent PV documentation
- Weak signal management or risk assessment processes
A targeted PV audit helps verify that previous findings have been properly addressed and that CAPAs are effective.
5. Changes in Staff or Vendor Responsibilities
Staff turnover, organisational restructuring, or outsourcing PV activities to a CRO or vendor can create compliance risks.
Why this matters:
- New personnel may not be fully trained in SOPs or regulatory requirements
- Vendor oversight may be insufficient or inconsistently documented
A PV audit ensures responsibilities are clearly defined, training is adequate, and third-party oversight is effective.
6. Quality and Process Improvement Opportunities
Even if there are no urgent compliance issues, a pharmacovigilance audit can be a proactive tool to optimise operations.
Benefits include:
- Streamlining ICSR processing and case triage
- Improving signal detection and risk management processes
- Identifying efficiency improvements and cost savings
- Supporting a culture of continuous quality improvement
A proactive audit demonstrates regulatory commitment and strengthens your PV governance framework.
How a Pharmacovigilance Audit Helps
A well-executed PV audit can provide:
- Regulatory confidence: Evidence that your system complies with MHRA, EMA, and other authority expectations
- Risk reduction: Identification and remediation of gaps before they become inspection findings
- Process efficiency: Streamlined workflows and improved documentation
- CAPA verification: Ensures corrective and preventive actions are implemented effectively
Whether your company is a small biotech, mid-size pharma, or CRO providing PV services, a pharmacovigilance audit ensures your safety processes are robust and inspection-ready.
Need Support with a Pharmacovigilance Audit?
Quality Vigilance provides internal, external, and vendor pharmacovigilance audits, GVP compliance assessments, CAPA remediation, and inspection readiness support for UK and EU pharmaceutical, biotech, and life science companies.
📩 Email: [email protected]
🌐 Website: www.qualityvigilance.com
📞 Phone: +44 7474 964491
Contact us today to discuss how a pharmacovigilance audit can improve compliance, streamline processes, and prepare your organisation for MHRA and EMA inspections.